[16] [23] Detecting a small increase in risk would require extremely large populations and prolonged follow-up periods
This final rule with comment period is also necessary to make updates to the ASC payment rates for CY 2026, enabling CMS to make changes to payment policies and payment rates for covered surgical procedures and covered ancillary services that are performed in ASCs in CY 2026
Higher doses are subject to the regulations for Therapeutic Use Exemptions (TUE)
The investigation specifically showed that these drugs did not increase the risk of any fractures, confirming their safety profile in clinical practice ( 4.6 Ophthalmological effects 4.6.1 Glaucoma GLP-1R agonists exhibit anti-inflammatory and neuroprotective properties, suggesting they could also be beneficial in neurodegenerative diseases ( A recent registry-based case-control study, summarized in Table 2 , involving 1,961 patients found that the use of GLP-1R agonists is linked to a lower risk of glaucoma (Sterling et al., 2021 ( Table 2 Clinical studies elucidating the use of antidiabetics against glaucoma
Thats kind of the rub, right? Ghiyam has heard similar reports from his patients
